Kornimate/medical-research-clean huggingface dataset:
icare® home vs goldmann applanation tonometry

Conditions: Glaucoma; Open Angle Glaucoma; Ocular Hypertension; Pseudo Exfoliation Syndrome

Summary: self-tonometry with icare home is regularly performed at sankt erik's eye hospital since a few years back. the purpose of this study was to show that the eye pressure measurements made with icare® home by patients / relatives do not vary more than those made with the standard method, goldman applanation tonometry (gat), by different healthcare professionals. this will hopefully confirm the usefulness of self-tonometry.

since a few years back, self-tonometry with icare® home has been available in glaucoma care. sankt erik's eye hospital was first in sweden to use the new technology. several studies have shown good agreement between measurements made by patients or healthcare professionals with icare® home and goldman applanation tonometry (gat). however, some researchers raise critical voices about the reliability of icare® home measurements because they can differ from gat. gat is considered the gold standard method of tonometry to which all other instruments are compared. but like all other methods, gat has some limitations. at the clinic, the eye pressure is usually measured with gat by different staff (ophthalmological nurses, opticians or doctors) from visit to visit. this can sometimes lead to pressure variations that may affect the follow-up of glaucoma patients. this raises the question of whether the difference between gat and icare® home is statistically and clinically significant. the purpose of this study was to show that the eye pressure measurements made with icare® home by patients / relatives do not vary more than those made with the standard method gat by different healthcare professionals. this will hopefully confirm the usefulness of self-tonometry.

Eligibility criteria:
inclusion criteria: * primary open angle glaucoma (poag) * pseudo-exfoliation glaucoma (pex) * ocular hypertension (oht) * no eye disease, exclusion criteria: * inability to perform measurements due to limited hand or arm mobility (eg rheumatism, tremor) * measurements outside the icare® home manufacturer's recommendations.

Keywords: intraocular pressure gat rebound tonometry self-tonometry icare® home
effects of lrygb on pharmacokinetics of nine cyp probe drugs

Conditions: Obesity, Morbid; Bariatric Surgery Candidate

Summary: due to anatomical and physiological changes caused by the roux-en-y gastric bypass (rygb) bariatric surgery, drug bioavailability after the surgery can be altered. therefore, post-operative dose adjustment in these patients can be required. the aim of the study was to investigate the effects of laparoscopic roux-en-y gastric bypass (lrygb) surgery on drug pharmacokinetics and cytochrome p450 (cyp) mediated metabolism using a cocktail of nine cyp probe drugs. the cocktail covers nine main cyp enzymes: melatonin (cyp1a2), nicotine (cyp2a6), bupropion (cyp2b6), repaglinide (cyp2c8), losartan (cyp2c9), omeprazole (cyp2c19/cyp3a4), dextromethorphan (cyp2d6), chlorzoxazone (cyp2e1), midazolam (cyp3a4). the changes in pharmacokinetic parameters of the drugs as well as modulation of the activity of cyps are evaluated before and one year after lrygb. in the study, the patients administering drug cocktail before surgery and 1 year after lrygb are served as their own controls.


Eligibility criteria:
inclusion criteria: * bmi \> 40 kg/m2 or bmi 35-40 kg/m2 and a comorbidity or its risk factor, such as type 2 diabetes, hypertension, sleep apnea, osteoarthritis of weight bearing joints or polycystic ovarian syndrome; * previous conservative treatment for obesity had been proven to be ineffective; * patients were assigned to undergo lrygb surgery * patients are able to give a written inform consent. exclusion criteria: * smokers * consuming alcohol more than 20 g per day were included in the study * taking drugs which alter cyps activity * history of hypersensitivity to the drugs used in the cocktail
tbtc study 25pk: intensive pharmacokinetic study of three doses of rifapentine and 25-desacetyl rifapentine

Conditions: Tuberculosis

Summary: primary objective: to compare the pharmacokinetics of rifapentine and 25-desacetyl rifapentine at three different doses: 600 mg, 900 mg, and 1200 mg. secondary objective: to describe any correlation between pharmacokinetic parameters of three different doses of rifapentine plus a standard dose of isoniazid and the occurrence of toxicity attributed to anti-tuberculosis treatment.

we will enroll 24-36 patients, 8-12 at each dose of 600, 900 and 1200 mg rifapentine admissions for pharmacokinetic studies will take place during the continuation phase of tuberculosis therapy. patients participating in a double-blinded trial of the tolerability and safety of higher doses of rifapentine during continuation phase therapy and consenting to participate in the pharmacokinetic study may be admitted to a clinical research center (crc) to allow for frequent blood sampling over a 24-hour period. otherwise, patients will be evaluated in the clinic.

Eligibility criteria:
inclusion: patients enrolled in tbtc study 25 informed consent exclusion: severe anemia (hct \<25%) any severe adverse event related to study drugs in tbtc study 25
hiv-heart aging study

Conditions: HIV Infections; Coronary Disease; Myocardial Infarction; HIV Encephalopathy; Aging; Heart Failure; Weight Gain

Summary: the hiv/heart aging study (hivh) is an ongoing, prospective, multicentre trial that was conducted to assess the incidence, the prevalence and the clinical course of cardiovascular diseases (cvd) in hiv-infected patients. the study population includes outpatients from specialized hiv-care units of the german ruhr region, who were at least 18 years of age, were known to have a hiv-infection and exhibited a stable disease status within 4 weeks before inclusion into the trial. from march 2004 (pilot phase) to october 2022 (15 year follow-up) 1858 hiv+ patients were recruited in a consecutive manner. the standardised examinations included a targeted assessment of medical history and physical examination. blood was drawn for comprehensive laboratory tests including hiv specific parameters (cd4 cell count, hiv-1 rna levels) and cardiovascular items (lipid concentrations, bnp values and renal parameters). furthermore, non-invasive tests were performed during the initial visit, including additional heart rate and blood pressure measurements, electrocardiogram (ecgs) and transthoracic echocardiography (tte). examinations were completed in accordance with previously defined standard operating procedures. cvd were defined as coronary, cerebrovascular, peripheral arterial disease, heart failure or cardiac vitium.

a comprehensive detailed description of the study procedures had been previously published (european journal of medical research 2007;12:243-248). comprehensive non invasive cardiovascular examination * anamnesis * file recherche,physical examination * documentation of the cardiovascular and antiretroviral medical therapy * electrocardiogram * transthoracic echocardiography (optional) * exercise electrocardiogram (optional) * exercise montreal cognitive assessment test (optional) * exercise the grooved pegboard test (optional) * blood and stool sample collection (optional) * questionnaire to quality of life and health economics

Eligibility criteria:
inclusion criteria: * age \> 18 years * known hiv-infection * signed informed consent exclusion criteria: * acute cardiovascular disease * unstable hemodynamic status in the three weeks before inclusion * pregnancy

Keywords: hiv aids antiretroviral therapy aging heart failure coronary heart desease myocardial infarction hiv-associated neurocognitive disorders weight gain
occlusal outcomes by ogs after a finishing protocol

Conditions: Malocclusion; Orthodontics

Summary: evaluation of the effects of the implementation of a new finishing protocol in orthodontics patients

patients who are being treated in the postgraduate orthodontic clinics and who meet the inclusion and exclusion criteria, will be subject to a detailed evaluation according to the ogs criteria and upon meeting the treatment completion criteria they will be placed an aligner with setup for 3 weeks. the scores obtained before and after the aligner will be compared with a historical control group the ogs score obtained for each group, will be compared and the impact of the protocol and the aligner will be evaluated

Eligibility criteria:
inclusion criteria: * patients who completed the active phase of the bimaxillary orthodontic treatment in the orthodontics postgraduate program of the udea by criteria of the treating clinician, during 2014 - 2018 period were included. patients treated by using the udea1 finishing protocol (gc) and the udea 2 (ge) finishing protocol, which included aligners. all patients must have standardized diagnostic records at the end of the finishing phase (cast models and panoramic x-rays) and must accepted to participate in the study voluntarily exclusion criteria: * patients that require prosthetic, periodontal and / or surgical treatments or with systemic compromise that may influence the outcome of orthodontic treatment

Keywords: finishing protocol aligner
after induction chemotherapy of dp plus ddp concurrent radiotherapy with and without bevacizumab study

Conditions: Head and Neck Neoplasms

Summary: this is a randomized, open controlled multicenter phase ii clinical study. the spss statistical software estimation of sample size, selection of the initial treatment of locally advanced head and neck squamous cell carcinoma in 120 patients, such as to achieve the desired results, considering expanding the clinical, according to the proportion of 1:1 were randomly divided into two groups, all patients were taken, docetaxel + cisplatin 2 cycles of induction chemotherapy 、concurrent chemoradiotherapy（tomotherapy+cisplatin）, the experimental group was added with avastin.


Eligibility criteria:
inclusion criteria: men and women are not limited, requirements of ecog0-2, age 18-70 years old, pathological stage iii (nccn2012), had not received radiotherapy and chemotherapy, expected to survive more than 3 months, the routine testing, were in the normal range, signed the informed consent exclusion criteria: do not meet the above criteria; allergic to docetaxel and avastin, or metabolic disorders; associated with gastrointestinal bleeding, perforation and other serious diseases; severe liver disease, kidney disease, respiratory disease or unable to control diabetes, hypertension and other chronic disease; heart disease clinical symptoms; there is peripheral nervous system disorders or have obvious mental disorder and disorders of the central nervous system; active phase \>ctcae2 clinical severe infection; a history of organ transplantation (including bone marrow transplantation of autologous peripheral stem cell transplantation); pregnant, lactating women, women of childbearing age and spouse refused to take effective means of contraception contraception; no legal capacity, continue to influence medical or ethical reasons for who
study of the clinical efficacy and safety of finerenone for the treatment of iga nephropathy

Conditions: Finerenone; IgA Nephropathy; Proteinuria; Safety Issues

Summary: iga nephropathy accounts for about 45 per cent of primary glomerular diseases in china and about 26 per cent of renal biopsies in patients with chronic failure.according to current guideline recommendations, there are limited indications for non-steroidal mras. therefore clinical studies to explore the range of clinical indications for fenetyllone are warranted.

primary iga nephropathy (igan) is an immunopathological diagnostic term for a type of glomerulonephritis characterised by the deposition of iga or iga-dominant immune complexes in the glomerular tunica albuginea. and in china iga nephropathy accounts for about 45% of primary glomerular diseases and about 26% of renal biopsies in patients with chronic failure. among them, about 15-40% of iga nephropathy patients progress to renal failure after 10-20 years; iga nephropathy has become one of the main causes of end-stage renal failure.the nonsteroidal salicorticoid receptor antagonist (mra)- finerenone reduces the risk of composite renal outcomes, eskd, or renal death in patients with type 2 diabetes and ckd.there are limited indications for non-steroidal mras. therefore clinical studies to explore the range of clinical indications for fenetyllone are warranted.

Eligibility criteria:
inclusion criteria: * primary igan diagnosed by renal biopsy; * receive rasi inhibitors for at least 3 months; * serum potassium \<5 mmol/l; * protein-to-creatinine ratio (pcr) \>0.3 mg/g exclusion criteria: * secondary igan; * autosomal dominant polycystic kidney disease or autosomal recessive polycystic kidney disease, lupus nephritis, lupus nephritis,; * previous renal transplantation; * chronic hepatic disease, malignant tumor, active malignancy, heart failure with ejection fraction \<40%; * followed up less than 6 months;

Keywords: finerenone iga nephropathy
canrestorefunction cancer-related fatigue ( crf )

Conditions: Breast Neoplasm

Summary: the goal of this randomized control trial is to determine if participating in an 8-week online cancer-related fatigue management intervention consisting of individualized exercise program, one-on-one goal setting and action plan development and interactive educational module will significantly reduce the perception of cancer-related fatigue, improve the quality of life, improve perceived cognition, and perceived function of breast cancer compared to a wait-list control group. the aim the project is to determine if an online cancerrelated fatigue management program is associated with 1. a decrease in cancer-related fatigue. 2. an improved perception of their ability and satisfaction in completing important activities 3. greater quality of life. 4. improved mobility 5. improved perceived cognition


Eligibility criteria:
inclusion criteria: * been diagnosed with any type of cancer within 5 years of enrollment, * received chemotherapy and/or radiation therapy * have access to mobile device or computer * have basic computer or mobile device skills, * have a significant level of fatigue defined as \>3 on 0-10 scale using the oneitem fatigue scale exclusion criteria: * have metastatic cancer (stage 4), * do not have a signed medical release by their physician or physician extender indicating that the participant can safely participate in the exercise program, * chronic fatigue prior to cancer diagnosis, such as fibromyalgia * are unable to follow verbal or written assessment instructions, are non-english speaking

Keywords: cancer-related fatigue breast cancer exercise problem-solving online interactive education
mind-body therapies for injury-related pain management in elite athletes

Conditions: Pain, Acute

Summary: this study will utilize a replicated single case experimental design (rscd) to investigate the effectiveness of a brief mindfulness meditation (mm) vs clinical hypnosis (hyp) training for improving pain in injured elite athletes. the primary outcome is change in pain intensity. it is hypothesized that: (1) both treatments will engender clinically meaningful improvement in pain intensity; (2) change in cognitive processes will be a unique mechanism underlying improved pain outcome in mm, and (3) change in cognitive content will be a unique mechanism underlying improved pain outcome in hyp. this research program has the potential to reduce athletes' uncertainty around pain, time out with injury and improve pain management during rehabilitation and recovery from injury.

the proposed program of research will utilize our current understanding of the behavioral inhibition system and behavioral activation system (bis-bas) model of pain and mind-body therapies and apply it to pain experienced by injured elite athletes. this study will be a replicated single case experimental design (rscd), which will investigate the effectiveness of a brief mindfulness meditation (mm) vs clinical hypnosis (hyp) training for improving the primary outcome of pain intensity in injured elite athletes. it will also investigate the potential mechanism role of change in cognitive content and cognitive processes in underlying the effects of these mind-body therapies. it is hypothesized that: (1) both treatments will engender clinically meaningful improvement in pain intensity; (2) change in cognitive processes will be a unique mechanism underlying improved pain outcome in mm, and (3) change in cognitive content will be a unique mechanism underlying improved pain outcome in hyp. this research program has the potential to reduce athletes' uncertainty around pain, time out with injury and improve pain management during rehabilitation and recovery from injury.

Eligibility criteria:
inclusion criteria: * be an elite athlete (i.e., competing at international or division 1 varsity level), * currently have a sport or exercise-related injury that resulted in an average pain intensity greater than or equal to 3 on a 0-10 numerical rating scale in the past week, and for which the predicted recovery time at the point of study enrolment is greater than 5 weeks, * be 18 or over. * read, speak, and understand the english language. * have access to the internet on a computer or smartphone. * have access to a set of headphones. * be willing to be randomly assigned to both conditions and listen to five 20-minute treatment sessions. * be willing to participate in a daily survey for 25 consecutive days.

Keywords: mindfulness meditation clinical hypnosis elite athletes
a real-world study of albumin-bound paclitaxel in the treatment of pancreatic cancer

Conditions: Pancreatic Cancer

Summary: pancreatic cancer progresses rapidly and has a higher death rate. albumin-bound paclitaxel is a new generation of paclitaxel . albumin-bound paclitaxel is recommended as a class 1a evidence treating patients with pancreatic cancer.the purpose of this study was to further observe and evaluate the clinical efficacy and safety of albumin-bound paclitaxel in the treatment of non-operative locally advanced or metastatic pancreatic cancer and to explore the prognostic factors .

this is a prospective, single-arm, observational study. after the subjects meet the inclusive and exclusive criteria, then they will receive albumin-bound paclitaxel treatment. the researchers can choose the treatment based on albumin-bound paclitaxel and choose dosage according to the patient's condition.

Eligibility criteria:
inclusion criteria: 1. age: 18 -80, male or female; 2. non-operative patients with locally advanced or metastatic pancreatic cancer diagnosed by pathology or histology (except islet cell carcinoma); 3. the patient has not received standard systematic treatment in the past, and the metastatic site has not received any local treatment, including radiotherapy, chemotherapy, surgical treatment, etc.; 4. at least one measurable lesion (ct scan length of tumor lesion is greater than 10 mm, ct scan short diameter of lymph node lesion is greater than 15 mm, scanning layer thickness is not greater than 5 mm); 5. the subjects volunteered to participate in this study and signed the informed consent form, with good compliance to follow-up. exclusion criteria: 1. pregnant or lactating women; 2. patients allergy to albumin-bound paclitaxel or its excipients 3. patients with albumin-bound paclitaxel contraindication; 4. doctors consider those who are not suitable for this study.

Keywords: pancreatic cancer albumin-bound paclitaxel
the 'hidden' biological impact of vitamin d deficiency: a biomarker study; part 2

Conditions: Vitamin D Deficiency

Summary: the investigators major aims are to: determine the vitamin d status of a group of young, apparently healthy adults in hong kong; examine inter-relationships between vitamin d status and biomarkers of dna damage and repair, oxidative stress, inflammation and endothelial health; and, in part 2 of the study, investigate effects of improvement in vitamin d status on these biomarkers and other measures of well-being in those young adults shown to be deficient in vitamin d.

in this part 2 of the study the investigators will investigate the effect of vitamin d supplementation on biomarkers of these 'hidden' changes in apparently healthy young adults. the investigators will also explore the effect of improvement in vitamin d status in young apparently healthy adults in regard to muscular strength and response time, glucose control, a hormone that is linked to vitamin d (parathyroid hormone (pth) ) and mood.

Eligibility criteria:
inclusion criteria: * apparently healthy, non-smokers * non-obese * found (in part1) to have low vitamin d status exclusion criteria: * chronic illness * serious illness requiring medical treatment in previous 6 months * pregnancy * on regular medication or taking supplements on a regular basis
the effect and applicability of cbt-based weight loss treatment model in obese patients with comorbid depression in health care

Conditions: Obesity; Depression; Cognitive Behavioral Therapy; Weight Loss

Summary: the aim of this study is find out how cbt-based weight loss program affects on eating behavior, weight loss, mood symptoms and risk for coronary heart diseases and type 2 diabetes and applicability of the program to obesity treatment among patients with comorbid depression. our hypothesis is that the cbt-based intervention improves long-term weight management results and supports positively the change in eating behavior and the risk for chd on type 2 dm. the study is randomized controlled one-year intervention study with 1 year follow-up. study subjects are adult obese (bmi\>35) subjects with comorbid depression. number of randomized study subjects will be 80, 40 in intervention group, 40 in control group. intervention group will proceed through a 52-week cbt-based weight loss group intervention. the aim of the intervention is to modify eating behavior and lifestyle factors affecting weight and weight maintenance. there will be 22 group counselling of 90 minutes divided in five modules and also three individual person-centered counselling visit, during which participants had an opportunity to discuss their personal concerns about diet and weight loss plan. control group will receive the usual care of obesity in kuopio university hospital. (4-8 individual 45-minute visit conducted by dieticians) study visits are at baseline and one and 2 years after baseline. for example eating behavior, health behavior, motivation and depression are studied with questionnaires. weight, waist circumference, height and blood pressure are measured. laboratory tests (lipid, glucose etc) are taken.


Eligibility criteria:
inclusion criteria: * age 18-65 years * diagnosed depression ( f32.0, f32.1, f32.2, f33.0, f33.1, f33.2) * bmi \> 35 exclusion criteria: * psychotic disorder, schizoaffective disorder, psychotic depression or bipolar disorder * severe current substance abuse * serious psychiatric condition (i.e self-destructive or impulsive behavior) * clinically significant illness contraindicating weight loss (i.e cancer or severe heart disease) * simultaneous participation in another weight loss program * severe vision, hearing, motoric deficiency